CURIS INC CRIS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-207.55
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $9.4M | -$7.6M | — | — | $5.5M |
| 2024 | $10.9M | -$43.4M | — | — | -$6.0M |
| 2023 | $10.0M | -$47.4M | — | -$38.4M | $19.7M |
| 2022 | $10.2M | -$56.7M | — | -$54.8M | $46.6M |
| 2021 | $10.6M | -$45.4M | — | -$37.6M | $90.7M |
| 2020 | $10.8M | -$29.9M | — | -$26.4M | $130.7M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -207.55 (distress)
- Working capital / assets -0.359
- Retained earnings / assets -62.475
- EBIT / assets -0.286
- Equity / liabilities 0.377
Source: SEC EDGAR filings · CIK 0001108205 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.